Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Latest Information Update: 09 Aug 2024
At a glance
- Drugs ELU 001 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Rectal cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Elucida Oncology
- 24 Jul 2024 Status changed from active, no longer recruiting to discontinued.
- 26 Jun 2024 Planned End Date changed from 15 Jun 2025 to 30 Sep 2024.
- 26 Jun 2024 Status changed from recruiting to active, no longer recruiting.